710 records found.
Aug 22, 2019
CStone announces data from trials of CS1001, CS1002 and CS1003 to be released for the first time at 2019 CSCO Annual Meeting
Aug 21, 2019
CMAB and Kintor Announce a New Comprehensive Collaboration to Develop and Manufacture the ALK-1 Monoclonal Antibody
Aug 19, 2019
Abstract on CStone's CS1001-101 trial accepted for poster presentation at ESMO 2019 Annual Congress
Aug 16, 2019
Oncopeptides Announces Acceptance of Data for Presentation at International Myeloma Workshop, September 12-15
Aug 16, 2019
AbbVie Receives FDA Approval of RINVOQ(TM) (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis
Aug 15, 2019
CStone Pharmaceuticals Reports First Half 2019 Financial Results
Aug 15, 2019
Regeneron Announces Upcoming Investor Conference Presentation
Aug 14, 2019
Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol
Aug 13, 2019
Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis
Aug 13, 2019
Novartis' Gilenya, Sanofi's Aubagio, Biogen's Tysabri and Tecfidera Capture the Majority of Recent Switches in the European Multiple Sclerosis Market Boosted by Frequent Neurologist Endorsement
Aug 12, 2019
PALM Ebola Clinical Trial Stopped Early as Regeneron's REGN-EB3 Therapy Shows Superiority to ZMapp in Preventing Ebola Deaths
Aug 06, 2019
Dupixent® (dupilumab) Approved by European Commission for Adolescents with Moderate-to-Severe Atopic Dermatitis
Aug 06, 2019
Dupixent® (dupilumab) Showed Positive Topline Results in Phase 3 Trial of Children Aged 6 to 11 Years with Severe Atopic Dermatitis
Aug 06, 2019
Provention Bio Reports Second Quarter 2019 Financial Results
Aug 06, 2019
Global Wet Age-Related Macular Degeneration Markets, 2014-2018 & 2019-2024 - Positive Clinical Trial Results and Increasing Approvals for Pipeline Drugs
Aug 06, 2019
Leap Presents Positive Clinical Results for the Combination of DKN-01 plus Keytruda® and Provides DKN-01 Program Update
Aug 05, 2019
Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments
Aug 01, 2019
Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Sustained Dose-Related Target Engagement Activity in a Multiple Ascending Dose Phase 1 Study
Aug 01, 2019
I-Mab Biopharma and TRACON Pharmaceuticals Announce Dosing of the First Patient in a Phase 1 Trial of the CD73 Antibody TJD5 in the U.S. in Patients with Advanced Solid Tumors
Aug 01, 2019
Monoclonal Antibody Therapeutics Market is Expected to Rise at 12.6% CAGR; Surging Cancer Cases Underpin Demand in Market - TMR

Pages